New Releases from NCBI BookshelfLorlatinib for untreated ALK-positive advanced non-small-cell lung cancer.Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer.
Post Content
Post Content
Helping patients make patient-centered treatment decisions requires treatment effect evidence aligned to the circumstances of individual patients. This evidence must
GARDP Antimicrobial Viewpoints are articles in which experts in different areas of antimicrobial resistance share their knowledge and opinions about